新型可移除经皮棘突间撑开器置入后的临床与影像学结局:初步经验
回顾性分析两个中心2019年采用可移除经皮棘突间撑开器(LobsterProject® Techlamed®)治疗症状性退变性腰椎管狭窄的59例患者,58例资料完整;3个月随访疼痛VAS从83±9降至29±19(-65%,p<0.001),ODI从31±12%降至13±10%(-58%,p<0.001),椎间孔面积从77±23 mm²增至95±27 mm²(+26%,p<0.001),并报告1例位置不佳、2例后移、1例棘突骨折。
要点
- 术后3个月VAS疼痛评分较术前降低65%(83±9降至29±19,p<0.001)。
- 术后3个月ODI功能评分较术前降低58%(31±12%降至13±10%,p<0.001)。
- CT示椎间孔面积从77±23 mm²增至95±27 mm²(+26%,p<0.001),观察者间信度Cronbach's alpha=0.899。
核心结论
- 经皮微创置入可移除棘突间撑开器显示出良好的安全性、3个月良好的临床结局以及椎间孔尺寸的解剖学增加。
研究设计与样本
- 回顾性研究,两个中心2019年连续治疗的症状性退变性腰椎管狭窄患者,59例接受治疗,58例资料完整(平均年龄71.2±9.2岁[55-92],男32例、女26例);48例在深度镇静下、10例在全麻下由两名介入放射科医生操作;临床评估采用VAS和ODI,影像学采用MRI或CT,椎间孔由两名放射科医生在术前和术后CT上独立测量;试验注册号NCT05203666,发布日期2022年1月21日,回顾性注册。
关键影像表现/征象
- 术后CT示椎间孔面积从77±23 mm²增至95±27 mm²(+26%,p<0.001),观察者间信度Cronbach's alpha=0.899。
- 术后出现1例位置不佳、2例3个月随访时后移、1例棘突骨折。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate clinical and radiological outcomes of a series of patients treated with a removable percutaneous interspinous process spacer (IPS) (LobsterProject® Techlamed®) for symptomatic degenerative lumbar spinal stenosis (DLSS).
METHODS: All patients treated in two centres with this IPS during 2019 were retrospectively reviewed. Procedures were performed under deep sedation or general anaesthesia by two interventional radiologists. Patients were clinically evaluated before intervention and at 3-month follow-up with Visual Analog Scales for pain (VAS), Oswestry Disability Index (ODI) and radiologically with MRI or CT scans. Neural foramina were independently measured for each patient on pre- and post-procedural CT scans by two radiologists.
RESULTS: Fifty-nine patients were treated in the selected period of which fifty-eight had complete documentation (mean age 71.2 ± 9.2 years [55-92], 32 males, 26 females). Forty-eight interventions were performed under deep sedation and ten under general anaesthesia, without procedural complications. Clinical follow-up at 3 months showed a significant reduction of pain (VAS from 83 ± 9 to 29 ± 19, - 65%; p < 0.001) and an improvement in functional outcomes (ODI from 31 ± 12 to 13 ± 10%, - 58%; p < 0.001). There was one case of unsatisfactory positioning post procedure, two cases of posterior migration at 3-month follow-up and one case of spinous process fracture. Mean neural foramina area increased from 77 ± 23 to 95 ± 27 mm2 (+ 26%; p < 0.001) with very good inter-observer reliability (Cronbach's alpha = 0.899).
CONCLUSION: Percutaneous minimally invasive insertion of a removable IPS device demonstrates a favourable safety profile, good clinical outcomes at 3 months, and apparent anatomical increase in foraminal dimensions.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05203666-Release Date: 21st January 2022, retrospectively registered.
引用
- Pavan, Dalili, De Vivo, et al. Clinical and radiological outcomes following insertion of a novel removable percutaneous interspinous process spacer: an initial experience. Neuroradiology. 2022. PMID: 35641830. doi:10.1007/s00234-022-02977-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。